Wegovy Prescription in Sherman, Texas at DFWPMA

Looking for a Wegovy prescription in Sherman, Texas? Wegovy (semaglutide) is a prescription GLP-1 medication used for chronic weight management and certain other medical indications. It requires careful medical evaluation because inappropriate prescribing or inadequate monitoring can lead to serious health complications.

At DFW Physicians Medical Associates (DFWPMA), our endocrinology and primary care providers conduct comprehensive evaluations of weight-related conditions, metabolic health, medical history, and treatment risks to determine whether Wegovy is safe and appropriate for each patient.

DFWPMA offers Wegovy prescription evaluations in Sherman and can prescribe Wegovy to eligible patients when medically appropriate. Wegovy is FDA-approved for chronic weight management in qualifying adults and adolescents aged 12 years and older, cardiovascular risk reduction in certain adults with obesity or overweight, and treatment of eligible adults with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis.

Book an appointment online or call (903) 957-0082 to contact our Sherman location.
Address: 📍
425 N Highland Ave., Suite 260, Sherman, TX 75092

Click here to get directions

We accept many major insurance plans. Not sure if your plan is accepted?

Call (903) 957-0082 and our team can help verify coverage.

Why Choose DFWPMA for a Wegovy Prescription in Sherman, Texas?

DFW Physicians Medical Associates provides Wegovy prescription evaluations in Sherman through medical providers experienced in endocrinology, metabolic health, weight management, and chronic disease treatment. Our multispecialty approach supports individualized assessments, appropriate prescribing decisions, and ongoing medical supervision.

Patients seeking a Wegovy prescription at DFWPMA can benefit from:

  • Experienced Medical Providers: Access to endocrinology and primary care providers experienced in metabolic health, diabetes care, and chronic disease management.
  • Comprehensive Eligibility Assessment: Evaluation of body mass index (BMI), weight-related conditions, treatment history, and potential contraindications before prescribing Wegovy.
  • Weight and Metabolic Health Evaluation: Assessment of obesity, blood glucose, blood pressure, cholesterol, and other metabolic indicators when clinically appropriate.
  • Individualized Prescription Decisions: Treatment recommendations based on medical eligibility, weight-management goals, clinical risks, and overall health.
  • Medication Safety Screening: Review of contraindications and precautions involving thyroid cancer history, pancreatitis, gastrointestinal disorders, gallbladder disease, and other relevant conditions.
  • Dosage Management and Monitoring: Individualized medication initiation, dose adjustments when appropriate, and monitoring for potential side effects.
  • Long-Term Weight Management: Ongoing evaluation of weight changes, metabolic health, treatment effectiveness, and sustainable lifestyle modifications.
  • Coordinated Multispecialty Care: Access to additional medical and behavioral health services when patients require comprehensive support for weight-related health concerns.

Wegovy is not appropriate for every patient seeking weight loss. Prescribing decisions require evaluating obesity-related health risks, potential adverse effects, contraindications, and alternative treatment options.

At DFWPMA Sherman, comprehensive medical evaluation and individualized treatment planning are central to determining whether Wegovy is an appropriate weight-management medication.

Schedule an appointment with DFWPMA Sherman to discuss Wegovy prescription eligibility and your weight-management options.

Meet Our Wegovy Prescription Providers in Sherman, Texas

DFWPMA Sherman offers Wegovy prescription evaluations through endocrinology and primary care providers whose clinical expertise includes weight management, metabolic disorders, diabetes care, and chronic disease management. These providers can assess medical eligibility and determine whether Wegovy is appropriate.

Gitana Staskus, MD – Endocrinology

Dr. Gitana Staskus is a board-certified endocrinologist with more than 20 years of clinical experience diagnosing and treating endocrine and metabolic disorders in adults and older adults.

Her expertise includes weight management, metabolic disorders, type 1 and type 2 diabetes, thyroid conditions, hormone disorders, and osteoporosis. Dr. Staskus emphasizes individualized treatment planning, patient education, and long-term management of endocrine conditions.

Her specialized background in weight management and metabolic health is particularly relevant for patients seeking Wegovy prescription evaluations, including individuals with obesity and related metabolic conditions.

Aniwelyn Tan, DNP – Primary Care

Aniwelyn Tan is an experienced primary care provider with more than 20 years of healthcare experience, including extensive work with chronic medical conditions and cardiovascular health.

Her clinical expertise includes obesity, weight management, diabetes, hypertension, internal medicine, and chronic disease treatment. She provides primary care services for patients ages 15 and older.

Her experience addressing obesity and metabolic conditions supports Wegovy prescription evaluations, including weight-related health assessments, medication safety reviews, and individualized treatment monitoring.

Ayodya Perera, MD – Family Medicine

Dr. Ayodya Perera is a family medicine physician providing preventive healthcare, comprehensive primary care, and chronic disease management for patients ages 15 and older.

Dr. Perera’s clinical interests include weight management, diabetes treatment, hypertension, preventive medicine, and patient-centered medical care. The physician emphasizes individualized treatment recommendations and shared decision-making.

This background in weight management and chronic disease care is relevant to Wegovy prescription evaluations, including assessing obesity-related health concerns, reviewing medical eligibility, and developing long-term treatment plans.

Book an appointment online to inquire about Wegovy prescription evaluations with DFWPMA’s medical providers in Sherman.

What Can a Wegovy Prescription in Sherman, Texas Help With?

Wegovy (semaglutide) is a GLP-1 receptor agonist approved for chronic weight management in eligible adults and adolescents, cardiovascular risk reduction in certain adults, and treatment of eligible adults with MASH and liver fibrosis. Wegovy supports weight loss by regulating appetite and reducing food intake.

At DFWPMA Sherman, Wegovy prescription evaluations address:

  • Obesity Treatment: Supporting chronic weight management in adults with a BMI of 30 or higher.
  • Overweight With Related Health Conditions: Treating eligible adults with a BMI of 27 or higher and a weight-related medical condition.
  • Chronic Weight Management: Supporting clinically meaningful weight loss and long-term weight maintenance.
  • Appetite Regulation: Reducing hunger and food intake through GLP-1 receptor activation.
  • Cardiovascular Risk Reduction: Reducing major cardiovascular events in eligible adults with cardiovascular disease and obesity or overweight.
  • Metabolic Liver Disease: Treating eligible adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis.
  • Adolescent Obesity: Supporting weight management in eligible adolescents aged 12 years and older.

Wegovy activates GLP-1 receptors involved in appetite regulation, helping patients feel fuller and consume fewer calories. Its effects can support substantial weight loss when combined with appropriate nutrition and physical activity.

The American College of Physicians recognizes semaglutide as an effective medication option for eligible adults with obesity or overweight and associated medical conditions.

Source: American College of Physicians – Pharmacologic Treatments for Overweight and Obesity

Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2. Important risks include pancreatitis, severe gastrointestinal reactions, dehydration-related kidney injury, and gallbladder disease.

Wegovy and Ozempic contain the same active ingredient, semaglutide, but have different approved indications. Wegovy is specifically approved for chronic weight management, while Ozempic is primarily prescribed for type 2 diabetes.

Schedule an appointment to discuss Wegovy prescription eligibility at DFWPMA Sherman.

What Wegovy Prescription Services Are Available at DFWPMA Sherman?

DFWPMA Sherman provides Wegovy prescription evaluations, weight and metabolic health assessments, medication safety reviews, treatment planning, and ongoing monitoring through endocrinology and primary care providers.

Our Wegovy prescription services include:

  • Initial Wegovy Prescription Evaluation: Reviewing BMI, medical history, weight-related conditions, and treatment eligibility.
  • Weight and Metabolic Health Testing: Assessing weight, blood glucose, cholesterol, and relevant metabolic markers.
  • Medication and Contraindication Review: Identifying medication interactions, contraindications, and potential health risks.
  • Wegovy Prescription and Treatment Planning: Prescribing Wegovy when medically appropriate and establishing weight-management goals.
  • Starting Dose and Titration: Adjusting dosage according to the prescribed formulation, treatment response, and tolerance.
  • Side Effect Monitoring: Assessing gastrointestinal symptoms, dehydration, and other adverse reactions.
  • Weight Loss and Treatment Response Monitoring: Tracking weight changes, medication effectiveness, and treatment progress.
  • Long-Term Weight and Metabolic Care: Managing obesity-related health conditions and supporting sustained weight management.
  • Alternative Weight Loss Medication Evaluation: Considering other approved medications when Wegovy is unsuitable.
  • Follow-Up and Coordinated Care: Providing continued medical supervision and specialty referrals when needed.

Wegovy injection typically starts at 0.25 mg once weekly for four weeks, followed by gradual dose increases. Wegovy tablets follow a different dosing schedule. Treatment adjustments depend on the prescribed formulation, medical response, and tolerance.

Common side effects include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. Severe abdominal pain, significant dehydration, or allergic reactions require prompt medical attention.

The American College of Physicians emphasizes individualized weight-management decisions that consider medication benefits, risks, costs, medical conditions, and long-term health goals.

Source: American College of Physicians – Pharmacologic Treatments for Overweight and Obesity

Not every patient qualifies for Wegovy. A medical evaluation determines whether the medication or an alternative treatment is appropriate. Wegovy should be discontinued when pregnancy is recognized, and patients planning pregnancy should discuss when to stop treatment with their physician.

Looking for a Wegovy prescription in Sherman, Texas? Book an appointment or call (903) 957-0082 to schedule your evaluation at DFWPMA.